The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
Read Full Article
#Moderna #PandemicFlu #VaccineDevelopment #USGovernment #PublicHealth
Read Full Article
#Moderna #PandemicFlu #VaccineDevelopment #USGovernment #PublicHealth
AP News
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine.
👍2🤬2
Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent COVID-19 infections.
Read Full Article
#COVID19 #SARSCoV2 #PeptideResearch #VaccineDevelopment #PublicHealth
Read Full Article
#COVID19 #SARSCoV2 #PeptideResearch #VaccineDevelopment #PublicHealth
The Japan Times
Japanese researchers develop peptide preventing COVID-19 infections
The peptide, which is a short chain of amino acids, has shown effectiveness in experiments involving various coronavirus strains.
🤔2
Experimental vaccine to prevent buildup of pathological tau in brain associated with Alzheimer’s dementia generated robust immune response in both mice 🐭 and non-human primates 🦧. Antibodies from immunized monkeys bound to tau protein in human blood samples 🩸. Researchers plan human clinical trials next 🧑⚕️.
Read Full Article
#AlzheimersResearch #VaccineDevelopment #Immunotherapy #TauProtein #ClinicalTrials
Read Full Article
#AlzheimersResearch #VaccineDevelopment #Immunotherapy #TauProtein #ClinicalTrials
UNM HSC Newsroom
UNM Researchers Plan Clinical Trials to Test Vaccine Against Alzheimer’s-Promoting Tau Protein
University of New Mexico Health Sciences researchers hope to launch human clinical trials in their quest for a vaccine to prevent the buildup of pathological tau – a protein in the brain associated with Alzheimer’s dementia.
❤3🤯2👨💻2👍1🤔1
TB bacteria ‘play dead’ to outlast vaccinated or previously infected hosts. 🦠🛡️ Genetic mouse study shows TB switches into a quiescent survival mode, relying on stress-response genes rather than growth factors, undermining traditional vaccine protection and guiding new vaccine plus therapy strategies. 💉🔬
Read Full Article
#Tuberculosis #TBResearch #VaccineDevelopment #QuiescentBacteria #HealthInnovation
Read Full Article
#Tuberculosis #TBResearch #VaccineDevelopment #QuiescentBacteria #HealthInnovation
Tufts Now
TB Bacteria Play Possum to Evade Vaccines
A vaccine protects more than 100 million infants each year from severe tuberculosis (TB), including the fatal brain swelling it can cause in babies and toddlers. But the vaccine doesn’t prevent adults from developing the more common form of TB that attacks…
👀3
Epstein-Barr virus appears to be trigger of lupus disease, say scientists. Connection of near-ubiquitous EBV to autoimmune disease affecting about 1 in 1,000 people may spur hunt for vaccine 💉🦠🔍.
Read Full Article
#EpsteinBarrVirus #LupusAwareness #AutoimmuneDisease #HealthResearch #VaccineDevelopment
Read Full Article
#EpsteinBarrVirus #LupusAwareness #AutoimmuneDisease #HealthResearch #VaccineDevelopment
the Guardian
Epstein-Barr virus appears to be trigger of lupus disease, say scientists
Connection of near-ubiquitous EBV to autoimmune disease affecting about 1 in 1,000 people may spur hunt for vaccine
Science News
Personalized vaccine shows promise against aggressive brain cancer (glioblastoma). People in early clinical trial had increased immune response, slowed tumor progression. The vaccine caused no serious side effects. One long-term survivor remains recurrence…
🧠 Personalized Vaccine Shows Promise Against Aggressive Brain Cancer
A phase 1 clinical trial for a personalized DNA-based vaccine, GNOS-PV01, targeting glioblastoma has shown encouraging results. The vaccine demonstrated safety and elicited robust immune responses, potentially increasing recurrence-free survival in a subset of patients.
📈 Improved Survival Rates and Immune Activation
In patients with an aggressive form of glioblastoma, the vaccine was linked to prolonged overall survival compared to historical outcomes. Two-thirds of patients did not have cancer progression at six months, and two-thirds survived one year, outperforming typical rates. One participant remains recurrence-free nearly five years later.
🔬 Novel Approach Targets Multiple Neoantigens
The vaccine activates a patient's immune system to recognize multiple unique tumor proteins (neoantigens) specific to their cancer. This DNA-based platform targets up to 40 cancer proteins per patient, twice the number targeted by previous cancer vaccines, aiming to overcome tumor evolution and the "cold tumor" environment.
#Glioblastoma #CancerResearch #VaccineDevelopment
A phase 1 clinical trial for a personalized DNA-based vaccine, GNOS-PV01, targeting glioblastoma has shown encouraging results. The vaccine demonstrated safety and elicited robust immune responses, potentially increasing recurrence-free survival in a subset of patients.
📈 Improved Survival Rates and Immune Activation
In patients with an aggressive form of glioblastoma, the vaccine was linked to prolonged overall survival compared to historical outcomes. Two-thirds of patients did not have cancer progression at six months, and two-thirds survived one year, outperforming typical rates. One participant remains recurrence-free nearly five years later.
🔬 Novel Approach Targets Multiple Neoantigens
The vaccine activates a patient's immune system to recognize multiple unique tumor proteins (neoantigens) specific to their cancer. This DNA-based platform targets up to 40 cancer proteins per patient, twice the number targeted by previous cancer vaccines, aiming to overcome tumor evolution and the "cold tumor" environment.
#Glioblastoma #CancerResearch #VaccineDevelopment
👏1
Science News
Vaccine protects against multiple fungal infections without hurting the gut Read Full Article #VaccineResearch #FungalInfections #GutHealth
🦠 A new vaccine, NXT-2, developed by University of Georgia researchers, shows success in preclinical animal models against life-threatening fungal infections.
🦠 This study is the first to evaluate a vaccine's impact on the gut microbiome's natural fungal and bacterial communities, finding NXT-2 protects against harmful fungi without significantly altering beneficial microbes.
🦠 NXT-2 has proven effective against the three most common fungal pathogens responsible for over 80% of fatal fungal infections, and also shows efficacy against the difficult-to-treat Candida auris.
#FungalInfections #VaccineDevelopment #GutHealth
🦠 This study is the first to evaluate a vaccine's impact on the gut microbiome's natural fungal and bacterial communities, finding NXT-2 protects against harmful fungi without significantly altering beneficial microbes.
🦠 NXT-2 has proven effective against the three most common fungal pathogens responsible for over 80% of fatal fungal infections, and also shows efficacy against the difficult-to-treat Candida auris.
#FungalInfections #VaccineDevelopment #GutHealth
❤3